Certificate of Analysis and Data Sheet
Human Urokinase (hUK)
Source:
Human urine
Catalog No.
ENZ-264
Description :
Urokinase (UK) is a serine protease, which is one of biological plasminogen activators. It is involved in a number of biological functions including fibrinolysis, embryogenesis, cell migration, tissue remodeling, ovulation, and wound healing.
It can be obtained from human urine or kidney cell culture.UK is a two-chain glycoprotein containing 411 amino acids with 12 dissulfide bonds.Its molecular weight is 54,000
Physical Appearance:
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation:
Lyophilized from a concentrated (1 mg/ml) solution in water containing no additives.
Solubility:
It is recommended to reconstitute the lyophilized hUK in sterile 18MΩ-cm
H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
Stability:
Lyophilized hUK although stable at room temperature for 3 weeks, should be stored desiccated
below -18 C. Upon reconstitution hUK should be stored at 4 C between 2-7 days and for future use
below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.
Purity:
Greater than 90.0% as determined by:
(a) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.
Specific Activity:
ProSpec's hUK conforms an activity greater than 68,000 IU/mg.
Activity:
1nM UK will cause a change in absorbance of 0.001 at 405 nm in 1 minute at R/T in 100 ul 0.05M Tris-HCl, 0.1M NaCl, pH 7.4, using S2444 (0.6mM) as the substrate.
Contaminants:
Less than: 0.1% hCG, 0.5%TSH, 0.5% LH, 0.5%GH and 0.5%Prl.
Protein content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm .
2. Analysis by RP-HPLC, using a standard
solution of hUK as a Reference Standard.
Usage:
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Latest Publications:
1. Evaluation of urokinase-type plasminogen activator and its receptor in neointima of polyester vascular grafts.
Pathophysiol Haemost Thromb 2005;34(1):23-8
2. Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination.
Cancer Res 2005 Nov 15;65(22):10464-71
3. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
Arthritis Res Ther 2005;7(6):R1244-53
4. Intermittent pneumatic compression of the foot and calf improves the outcome of catheter-directed thrombolysis using low-dose urokinase in patients with acute proximal venous thrombosis of the leg.
J Vasc Surg 2005 Nov;42(5):940-4
5. Emergent basilar artery and bilateral posterior cerebral artery angioplasty, urokinase thrombolysis, and stenting for acute basilar artery occlusion secondary to diagnostic cardiac catheterization: case presentation.
J Neuroimaging 2005 Oct;15(4):315-8
6. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Chest 2005 Oct;128(4):2316-26